InfuSystem Holdings (INFU) AI Stock Analysis

• Market Cap: $220.19M
• Dividend Yield: N/A
• Average Volume (3M): 275.69K
• Price to Earnings (P/E): 44.6
• Beta (1Y): 1.59
• Revenue Growth: 8.13%
• EPS Growth: 1293.06%
• Country: US
• Employees: 502
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.12
• Shares Outstanding: 20,425,964
• 10 Day Avg. Volume: 335,464
• 30 Day Avg. Volume: 275,692
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 1.15
• Enterprise Value/Gross Profit: 2.11
• Enterprise Value/Ebitda: 6.77
• 1Y Price Target: $14.00
• Price Target Upside: 32.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 70 Outperform
• Price Target: $10.50 ▼(-0.76% Downside)

InfuSystem Holdings demonstrates robust financial performance and strategic initiatives, particularly in revenue growth and cash flow. However, high valuation metrics and overbought technical indicators suggest caution. The earnings call and corporate events provide a positive outlook, but challenges in specific segments temper the overall score.

Positive Factors

Financial Performance

The Company showed notable progress in gross margin improvement of 122 basis points Y/Y and AEBITDA margin improvement of 282 basis points Y/Y.

Operating Cash Flow

Operating cash flow was $20.5M in 2024, an 82% increase Y/Y.

Negative Factors

Earnings

EPS of $0.04 was below our estimate and consensus of $0.08 and $0.09, respectively.

Revenue

Revenue came in below our forecast and consensus due to delays in onboarding new wound care initiatives as the Company looks to improve referral processes with newer partners.

InfuSystem Holdings Business Overview & Revenue Model

Company Description

InfuSystem Holdings, Inc. (INFU) is a leading provider of infusion pumps and related services, primarily serving the healthcare sector. The company specializes in the rental and sale of infusion pumps, as well as providing a comprehensive suite of services, including maintenance, logistics, and patient support. InfuSystem's core products cater to various medical applications, including pain management, chemotherapy, and antibiotic therapies, making it an essential partner for hospitals, clinics, and home healthcare providers.

How the Company Makes Money

InfuSystem generates revenue through multiple key streams, primarily from the rental and sale of infusion pumps and related equipment. The company charges healthcare facilities for the leasing of their infusion devices, which can include both short-term and long-term contracts. Additionally, InfuSystem earns income through the provision of consumables, such as IV administration sets and related supplies necessary for the operation of their infusion systems. Service agreements, which encompass maintenance, repair, and technical support, also contribute significantly to the company's revenue. Strategic partnerships with healthcare providers and manufacturers further enhance their market reach and service offerings, allowing InfuSystem to secure recurring revenue and build long-term customer relationships.

InfuSystem Holdings Financial Statement Overview

Summary

InfuSystem Holdings shows strong revenue growth and cash flow generation, with a stable gross profit margin. The company has improved its leverage position and return on equity, although profitability margins could be enhanced.

Income Statement

InfuSystem Holdings has demonstrated strong revenue growth, particularly in the TTM period, with a 1.68% increase. The gross profit margin has remained stable around 54.5%, indicating efficient cost management. However, the net profit margin is relatively low at 4.84%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are healthy, reflecting solid operational performance.

Balance Sheet

The company's debt-to-equity ratio has improved over time, currently at 0.56, indicating a balanced approach to leveraging. Return on equity has increased to 12.15% in the TTM period, showcasing better utilization of equity. However, the equity ratio is moderate, suggesting a need for cautious financial management to maintain stability.

Cash Flow

InfuSystem Holdings has shown impressive growth in free cash flow, with a 29.68% increase in the TTM period. The operating cash flow to net income ratio is strong at 1.67, indicating efficient cash generation relative to earnings. The free cash flow to net income ratio of 0.79 suggests effective conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	139.89M	134.86M	125.78M	109.91M	102.38M	97.39M
Gross Profit	76.30M	70.40M	63.11M	62.57M	60.20M	58.76M
EBITDA	23.80M	20.03M	16.50M	14.89M	17.15M	22.82M
Net Income	5.07M	2.35M	872.00K	18.00K	1.42M	17.33M
Balance Sheet
Total Assets	100.85M	103.61M	102.92M	99.39M	97.59M	96.99M
Cash, Cash Equivalents and Short-Term Investments	720.00K	527.00K	231.00K	165.00K	186.00K	9.65M
Total Debt	30.45M	28.42M	36.37M	36.92M	36.77M	42.66M
Total Liabilities	46.31M	46.09M	50.61M	51.38M	49.31M	56.24M
Stockholders Equity	54.53M	57.53M	52.30M	48.00M	48.27M	40.75M
Cash Flow
Free Cash Flow	21.06M	2.63M	106.00K	2.44M	1.66M	3.37M
Operating Cash Flow	26.56M	20.46M	11.22M	17.52M	18.32M	20.28M
Investing Cash Flow	-10.47M	-13.24M	-6.73M	-11.48M	-21.32M	-12.16M
Financing Cash Flow	-15.52M	-6.92M	-4.42M	-6.06M	-6.46M	-1.12M

InfuSystem Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INFU, the sentiment is Positive. The current price of 10.58 is above the 20-day moving average (MA) of 9.54, above the 50-day MA of 7.37, and above the 200-day MA of 7.04, indicating a bullish trend. The MACD of 1.00 indicates Negative momentum. The RSI at 79.89 is Negative, neither overbought nor oversold. The STOCH value of 75.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INFU.

InfuSystem Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	77 Outperform	$199.43M	16.44	10.39%	1.98%	-16.64%	-13.64%
INFU	70 Outperform	$220.19M	44.60	9.39%	―	8.13%	1293.06%
STXS	66 Neutral	$246.80M	―	-198.62%	―	33.94%	-6.91%
SMTI	61 Neutral	$299.65M	―	-25.78%	―	34.29%	-49.21%
KRMD	59 Neutral	$195.11M	―	-25.63%	―	19.57%	61.81%
Sector *	51 Neutral	$7.89B	-0.33	-41.61%	2.23%	23.26%	-2.03%
MLSS	40 Underperform	$46.36M	―	-123.50%	―	7.84%	-43.00%

InfuSystem Holdings Corporate Events

InfuSystem Holdings to Announce Q2 2025 Results

InfuSystem Holdings, Inc. announced it will release its second quarter 2025 financial results on August 5, 2025, before the market opens. The company will also host a conference call on the same day to discuss the financial results, providing stakeholders with insights into its financial performance and strategic direction.

InfuSystem Holdings Extends Credit Agreement Maturity Date

On July 15, 2025, InfuSystem Holdings, Inc. and its subsidiaries entered into a Second Amendment to their Credit Agreement with JPMorgan Chase Bank, extending the maturity date to July 15, 2030. This amendment signifies a strategic financial maneuver, potentially enhancing the company’s financial stability and operational flexibility, which may positively impact its market positioning and stakeholder confidence.